Dear Colleagues,

Among emerging Asian markets, South Korea is quickly becoming a dominant outsourcing location for clinical trials. This is mostly due to a quickly evolving regulatory environment, streamlined regulatory approval, reduced costs, and more successful patient recruitment relative to many developed Western countries.

We have recently published an article in the May issue of the International Clinical Trials magazine entitled "Korea Path" (pp 30-36) which discusses the country's current clinical research environment, including the challenges that must be addressed by foreign companies.

What are the translation requirements? How do cultural differences affect medical practices? What is the current regulatory approval process?

We hope you take this opportunity to read the article, and that it provides you with new and useful information.

Please also check out our other recent publications to learn more about global clinical trials and biomanufacturing.

As a language service provider for over fifteen years, we are well aware of the importance of native language communication, especially in the translation of clinical trial documents. Our life science experts have translation experience in over one hundred languages, including Korean, and other dominant Asian languages.